» Articles » PMID: 21337594

Equivalence of Improvement in Area Under ROC Curve and Linear Discriminant Analysis Coefficient Under Assumption of Normality

Overview
Journal Stat Med
Publisher Wiley
Specialty Public Health
Date 2011 Feb 22
PMID 21337594
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

In this paper we investigate the addition of new variables to an existing risk prediction model and the subsequent impact on discrimination quantified by the area under the receiver operating characteristics curve (AUC of ROC). Based on practical experience, concerns have emerged that the significance of association of the variable under study with the outcome in the risk model does not correspond to the significance of the change in AUC: that is, often the variable is significant, but the change in AUC is not. This paper demonstrates that under the assumption of multivariate normality and employing linear discriminant analysis (LDA) to construct the risk prediction tool, statistical significance of the new predictor(s) is equivalent to the statistical significance of the increase in AUC. Under these assumptions the result extends asymptotically to logistic regression. We further show that equality of variance-covariance matrices of predictors within cases and non-cases is not necessary when LDA is used. However, our practical example from the Framingham Heart Study data suggests that the finding might be sensitive to the assumption of normality.

Citing Articles

The Harms of Class Imbalance Corrections for Machine Learning Based Prediction Models: A Simulation Study.

Carriero A, Luijken K, de Hond A, Moons K, Van Calster B, van Smeden M Stat Med. 2025; 44(3-4):e10320.

PMID: 39865585 PMC: 11771573. DOI: 10.1002/sim.10320.


R2ROC: an efficient method of comparing two or more correlated AUC from out-of-sample prediction using polygenic scores.

Momin M, Wray N, Lee S Hum Genet. 2024; 143(9-10):1193-1205.

PMID: 38902498 DOI: 10.1007/s00439-024-02682-1.


COVID-19 and the Importance of Being Prepared: A Multidisciplinary Strategy for the Discovery of Antivirals to Combat Pandemics.

Galvez-Llompart M, Zanni R, Galvez J, Basak S, Goyal S Biomedicines. 2022; 10(6).

PMID: 35740363 PMC: 9220014. DOI: 10.3390/biomedicines10061342.


How Molecular Topology Can Help in Amyotrophic Lateral Sclerosis (ALS) Drug Development: A Revolutionary Paradigm for a Merciless Disease.

Galvez-Llompart M, Zanni R, Garcia-Domenech R, Galvez J Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056151 PMC: 8781553. DOI: 10.3390/ph15010094.


Estimation of required sample size for external validation of risk models for binary outcomes.

Pavlou M, Qu C, Omar R, Seaman S, Steyerberg E, White I Stat Methods Med Res. 2021; 30(10):2187-2206.

PMID: 33881369 PMC: 8529102. DOI: 10.1177/09622802211007522.